menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Innovations in the Treatment of LA SCCHN: Enhancing Antitumor Activity through IAP Antagonism

Are antagonists of inhibitor of apoptosis proteins likely to improve patient outcomes in LA SCCHN? Do you know the critical data? If not, you should!

Live Meeting
Information
October 24, 2022
06:00 PM - 07:00 PM CDT
Grand Hyatt San Antonio | Room: Lonestar Salon A/B
600 E Market St, San Antonio, TX 78205, San Antonio, Texas, United States
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    This symposium will examine the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of LA SCCHN. The cisplatin-based chemoradiation that is the current standard of care for these patients offers only limited overall survival and is accompanied by early and late toxicities. As such, the emergence of antagonists of IAPs, with a unique MOA and the potential to dramatically improve treatment outcomes and the quality of life for patients with LA SCCHN, could be a game changer. Our expert faculty present clinical data that support the potential inclusion of antagonists of IAPs in the management of LA SCCHN and discuss when this treatment is likely to enter the clinic. Join us and learn why antagonists of IAPs may represent one of the most important breakthroughs over the last 30 years in the management of LA SCCHN.

  • Program Schedule

    Segment

    Faculty

    Welcome and Introduction

    Kevin Harrington, MD

    Raising Awareness of Emergent Findings in the Treatment of LA SCCHN

    Barbara Burtness, MD

    Why the Excitement Associated with IAP Antagonists in LA SCCHN?

    Ari Rosenberg, MD

    Focus on Inhibitor of Apoptosis Protein (IAP) Antagonists Mechanism of Action in the Tumor Microenvironment (shown in 3D)

    Kevin Harrington, MD

    Panel Discussion:IAP Antagonists in LA SCCHN: New Potential Options for Patients

    Kevin Harrington, MD (moderator)

    Barbara Burtness, MD

    Ari Rosenberg, MD

    Q&A and Closing Remarks

    Kevin Harrington, MD (moderator)

    Barbara Burtness, MD

    Ari Rosenberg, MD

    *subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kevin Harrington, MD
    Head of Division of Radiotherapy and Imaging
    The Institute of Cancer Research
    London, UK

    Faculty:
    Barbara Burtness, MD
    Professor of Medicine
    Co-Leader, Developmental Therapeutics Program
    Interim Associate Director, Diversity, Equity and Inclusion
    Yale Cancer Center, Yale School of Medicine
    New Haven, CT 

    Ari Rosenberg, MD
    Assistant Professor of Medicine
    Assistant Professor Section of Hematology/Oncology
    University of Chicago Medicine
    Chicago, IL

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Brad Bongiovanni, ND, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Peer Review, if applicable
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe factors that contribute to patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) experiencing disease progression/recurrence
    2. Assess the risks, benefits, and limitations of currently available treatment options for the management of LA SCCHN
    3. Differentiate the mechanisms of action of agents currently being investigated for the treatment of LA SCCHN from those of currently available treatment options

    Assess the therapeutic potential of agents being investigated for the management of LA SCCHN

  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, radiation oncologists, and other healthcare professionals treating patients with head and neck cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Live Satellite Symposium activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 hour of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Anna Trentini prior to the live event at atrentini@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    This symposium will examine the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of LA SCCHN. The cisplatin-based chemoradiation that is the current standard of care for these patients offers only limited overall survival and is accompanied by early and late toxicities. As such, the emergence of antagonists of IAPs, with a unique MOA and the potential to dramatically improve treatment outcomes and the quality of life for patients with LA SCCHN, could be a game changer. Our expert faculty present clinical data that support the potential inclusion of antagonists of IAPs in the management of LA SCCHN and discuss when this treatment is likely to enter the clinic. Join us and learn why antagonists of IAPs may represent one of the most important breakthroughs over the last 30 years in the management of LA SCCHN.

  • Program Schedule

    Segment

    Faculty

    Welcome and Introduction

    Kevin Harrington, MD

    Raising Awareness of Emergent Findings in the Treatment of LA SCCHN

    Barbara Burtness, MD

    Why the Excitement Associated with IAP Antagonists in LA SCCHN?

    Ari Rosenberg, MD

    Focus on Inhibitor of Apoptosis Protein (IAP) Antagonists Mechanism of Action in the Tumor Microenvironment (shown in 3D)

    Kevin Harrington, MD

    Panel Discussion:IAP Antagonists in LA SCCHN: New Potential Options for Patients

    Kevin Harrington, MD (moderator)

    Barbara Burtness, MD

    Ari Rosenberg, MD

    Q&A and Closing Remarks

    Kevin Harrington, MD (moderator)

    Barbara Burtness, MD

    Ari Rosenberg, MD

    *subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kevin Harrington, MD
    Head of Division of Radiotherapy and Imaging
    The Institute of Cancer Research
    London, UK

    Faculty:
    Barbara Burtness, MD
    Professor of Medicine
    Co-Leader, Developmental Therapeutics Program
    Interim Associate Director, Diversity, Equity and Inclusion
    Yale Cancer Center, Yale School of Medicine
    New Haven, CT 

    Ari Rosenberg, MD
    Assistant Professor of Medicine
    Assistant Professor Section of Hematology/Oncology
    University of Chicago Medicine
    Chicago, IL

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Brad Bongiovanni, ND, has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Peer Review, if applicable
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Describe factors that contribute to patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) experiencing disease progression/recurrence
    2. Assess the risks, benefits, and limitations of currently available treatment options for the management of LA SCCHN
    3. Differentiate the mechanisms of action of agents currently being investigated for the treatment of LA SCCHN from those of currently available treatment options

    Assess the therapeutic potential of agents being investigated for the management of LA SCCHN

  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, radiation oncologists, and other healthcare professionals treating patients with head and neck cancers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this Live Satellite Symposium activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 hour of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”  

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Anna Trentini prior to the live event at atrentini@glc.healthcare.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Schedule25 Sep 2022
Webpack App